Drawing on the elucidated biology of ASXL1 mutations, findings from the company’s clinical trials in acute myeloid leukaemia (AML), and reports of the frequent occurrence of ASXL1 mutations in certain ...

SELLAS Life Sciences Group has announced positive data from preclinical studies identifying the ASXL1 mutation as a significant predictor of response to SLS009, a selective cyclin-dependent kinase ...

Based on elucidated biology of ASXL1 mutations, results from SELLAS’ clinical trials in acute myeloid leukemia (AML), and reports of common occurrence of ASXL1 mutations in some solid cancers ...

Based on elucidated biology of ASXL1 mutations, results from SELLAS’ clinical trials in acute myeloid leukemia (AML), and reports of common occurrence of ASXL1 mutations in some solid cancers, the ...

Drawing on the elucidated biology of ASXL1 mutations, findings from the company’s clinical trials in acute myeloid leukaemia (AML), and reports of the frequent occurrence of ASXL1 mutations in ...

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...

In addition, we are seeing more than 50% ORR to date in our expansion cohorts in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation and mutations and cytogenic changes ...